Kura Oncology (NASDAQ:KURA) Given Outperform Rating at Wedbush

Wedbush restated their outperform rating on shares of Kura Oncology (NASDAQ:KURA) in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a $36.00 target price on the stock.

Several other research analysts also recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Kura Oncology in a report on Monday, April 28th. JMP Securities reaffirmed a “market outperform” rating and issued a $28.00 price objective on shares of Kura Oncology in a research note on Wednesday, June 4th. Barclays reduced their target price on shares of Kura Oncology from $32.00 to $11.00 and set an “overweight” rating on the stock in a report on Friday, May 2nd. Mizuho cut their price target on shares of Kura Oncology from $32.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, May 19th. Finally, UBS Group decreased their price objective on Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $24.50.

Kura Oncology Price Performance

Kura Oncology stock opened at $5.85 on Friday. The stock has a fifty day moving average of $6.18 and a 200-day moving average of $7.34. The stock has a market capitalization of $506.43 million, a P/E ratio of -2.79 and a beta of 0.40. The company has a debt-to-equity ratio of 0.02, a quick ratio of 8.07 and a current ratio of 8.07. Kura Oncology has a 52 week low of $5.41 and a 52 week high of $23.48.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.15). The firm had revenue of $14.11 million for the quarter, compared to analysts’ expectations of $39.08 million. On average, sell-side analysts expect that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kura Oncology

Institutional investors and hedge funds have recently made changes to their positions in the stock. State of Wyoming acquired a new position in Kura Oncology during the 1st quarter worth approximately $48,000. Virtus ETF Advisers LLC increased its holdings in shares of Kura Oncology by 71.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock valued at $64,000 after acquiring an additional 3,061 shares in the last quarter. Pallas Capital Advisors LLC acquired a new position in shares of Kura Oncology during the first quarter worth approximately $66,000. Flower City Capital bought a new position in shares of Kura Oncology in the 1st quarter worth $79,000. Finally, Magnetar Financial LLC bought a new position in shares of Kura Oncology in the 1st quarter worth $79,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.